Novaerus Protect 800 Irish Plasma Air Disinfection Device
NOVAERUS uses patented active purification technology to continuously pull contaminated indoor air across internal short-exposure plasma coils, deactivating airborne microorganisms and viruses at the DNA level.
The recent coronavirus outbreak highlights the vital role of airborne transmission in the spread of infection. Breathing, talking, coughing, and sneezing can release airborne pathogens into the air, with sizes ranging from submicron particles to large droplets. Novaerus technology has been tested against MS2 Bacteriophage, a commonly used surrogate for SARS-CoV (Coronavirus), reducing the airborne virus by 99.99%.
Designed for continuous air dis-infection and odour control in medium indoor spaces, the Novaerus Protect 800 (NV800) uses patented filter-free ultra-low energy plasma technology with a 2-speed fan. Can be wall-mounted or placed on a stand and plugs into any outlet.
Suggested application area: 400 – 800 平方呎ft2
CONFORMS to the Medical Device Directive
Plasma: The Fourth State of Matter
Novaerus uses a patented atmospheric plasma discharge of the dielectric barrier discharge type. The plasma discharge comprises electrons and ions that cause extensive damage to microorganisms. Unlike other products, microorganisms are exposed directly to the plasma discharge as opposed to by-products of the discharge.
Novaerus plasma is powerful, yet gentle. With no harmful byproducts, it is safe for use around children, the elderly, and the sick. Novaerus portable units are simple to use, low-maintenance and highly effective for rapid or continuous infection control, odour mitigation, and particle reduction.
Remove Airborne Pathogens & Pollutants in Intensive Care Units
ICU and oncology patients are at heightened risk for healthcare-acquired infections due to the severity of their illness. ICU patients typically have a compromised immune system, long length of hospital stay, several caregivers performing multiple tasks, and a high quantity of invasive devices being used. All of these factors contribute to a greater potential for contact with biological or environmental contamination.
How Novaerus Compares
Compare Novaerus with other air purification technologies.
(1 = Not Effective 5 = Very Effective)
Tested & Proven
Novaerus technology has been shown to be safe and effective in dozens of laboratory tests, case studies, and clinical trials conducted around the world.
Clostridium difficile Spore Reduction
Novaerus Defend 1050 was shown to reduce 99.6% of airborne C. difficile within the first 20 minutes of operation and >99.9% after 40 minutes.
TAGS: AIRMID, IRELAND, NV1050, BACTERIA
Mycobacterium tuberculosis Bacteria Reduction
Novaerus Defend 1050 was shown to reduce the concentration of M. smegmatis (surrogate for M. tuberculosis) by 97% after 30 minutes of operation.
TAGS: NV1050, TB, AIRMID, BACTERIA, TB
Formaldehyde Reduction
Novaerus Protect 800/900 was shown to reduce formaldehyde by 85% during a 14-hour testing experiment.
TAGS: NV800/900, AVOMEEN, VOC, MICHIGAN, US, VOC
Influenza A Reduction
Novaerus Defend 1050 was shown to reduce 99.9% of airborne Influenza A within the first 10-20 minutes of operation.
TAGS: AIRMID, IRELAND, NV1050, VIRUS
Particle Reduction
Novaerus Defend 1050 removed 99% of PM2.5 within 6.26 minutes and 99% of PM1.0 within 6.33 minutes.
TAGS: NV1050, CAMFIL, PARTICLES, SWEDEN
Staphylococcus epidermidis Bacteria Reduction
Novaerus Defend 1050 achieved a microbial cell reduction of 99.94% of Staphylococcus epidermidis within 15 minutes of operation.
TAGS: NV1050, BACTERIA, MRSA, IRELAND
Airborne Allergen Reduction
Novaerus Protect 800/900 was shown to reduce overall allergens by 41.16%, including house dust mites, feline dander, canine dander, and pollen.
TAGS: NV800/900, INDOOR BIOTECHNOLOGIES, WALES, UK, ALLERGIES
Methicillin-resistant Staphylococcus aureus (MRSA) Reduction
Novaerus Protect 800/900 reduced 99.99% of methicillin-resistant Staphylococcus aureus (MRSA) bacteria over the course of four hours.
TAGS: NV800, NV900, MICROBAC, NORTH CAROLINA, US, BACTERIA
Significant impact at long term care facility
Comparison of nosocomial infection rates for the June to September period, 2012 vs. 2013
RB Health Partners, Inc., December 3, 2013
Every floor at long term care facility improved
Comparison of nosocomial infection rates
RB Health Partners, Inc., May 2015
Novaerus portable deployment against influenza
- MS2 virus – surrogate for influenza and Norovirus
- Results: 4.4 log (> 99.99%) reduction
- Test Lab: Aerosol Research and Engineering labs (ARE Labs, Olathe, Kansas)
Application
- Patient Rooms
- Operating Theatres
- Nurses Station
- Examination Room